SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Jesse Owens

PatientJesse Owens
Date of birth1960-09-12
IdentifiersMRN HR-ML042-SYN; SSN (made up) 000-42-8319
Document date2026-08-05
AuthorClarence Whitfield-Arroyo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review after three cycles: restaging CT and the decision for surgery. [S]

History of Present Illness

Mr. Owens returns three weeks after his third cycle. The cold he had at the sick visit cleared in a week, and the third cycle went ahead on schedule. Restaging CT five days ago shows the nodule shrunk from 2.9 to 1.3 cm and the interlobar node from 1.6 to 0.8 cm, with nothing new. The thoracic surgeon has booked a thoracoscopic left upper lobectomy in two weeks. He finished 16 prehabilitation sessions and walks 3 km again. He has not smoked for nine weeks. He feels a little more tired than usual, without cold intolerance, weight gain or constipation. He has had no thoughts of self-harm. [S]

ElementDetail
Restaging CTPartial response: primary 1.3 cm (from 2.9), node 0.8 cm (from 1.6); no new disease
Planned operationThoracoscopic left upper lobectomy with lymph node dissection in two weeks
TobaccoAbstinent nine weeks

Review of Systems

SystemResultFinding
ConstitutionalPositiveSlightly more tired than usual; weight 75.2 kg; no fever
RespiratoryNegativeCough gone since the cold cleared; no breathlessness
EndocrineNegativeNo cold intolerance, weight gain or constipation
GastrointestinalNegativeNo diarrhea or nausea
IntegumentaryNegativeNo rash
PsychiatricNegativeMood good; PHQ-2 1

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 80.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7Oral route2026-05-26 to 2026-06-01completedS
Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse1 mg twice daily after foodOral route2026-06-02activeS
Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial)Day 1 every 21 days for three cyclesIntravenous route2026-06-03 to 2026-07-15completedS
Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cyclesDay 1 every 21 days for three cyclesIntravenous route2026-06-03 to 2026-07-15completedS
Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cyclesDay 1 every 21 days for three cyclesIntravenous route2026-06-03 to 2026-07-15completedS
Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the lastOne tablet dailyOral route2026-05-26 to 2026-08-05completedS
Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed)1000 mcg once; a second dose was not due before pemetrexed endedIntramuscular route2026-05-26 to 2026-05-26completedS
Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose4 mg twice daily for three days around each cycleOral route2026-06-02 to 2026-07-16completedS
Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy8 mg every 8 hours as neededOral route2026-06-03 to 2026-07-31completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-05Body height178cmS
2026-08-05Body weight75.2kgS
2026-08-05Body mass index (BMI) [Ratio]23.7kg/m2S
2026-08-05Systolic blood pressure124mm[Hg]S
2026-08-05Diastolic blood pressure76mm[Hg]S
2026-08-05Heart rate72/minS
2026-08-05Respiratory rate14/minS
2026-08-05Body temperature36.5CelS
2026-08-05Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-05Hemoglobin [Mass/volume] in Blood12.8g/dL13.5-17.5 g/dLLowS
2026-08-05Leukocytes [#/volume] in Blood by Automated count6.210*3/uL4-11 10*3/uLNormalS
2026-08-05Neutrophils [#/volume] in Blood by Automated count3.610*3/uL1.5-7.7 10*3/uLNormalS
2026-08-05Platelets [#/volume] in Blood by Automated count18810*3/uL150-400 10*3/uLNormalS
2026-08-05Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-08-05Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-08-05Creatinine [Mass/volume] in Serum or Plasma1.1mg/dL0.7-1.3 mg/dLNormalS
2026-08-05Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M74mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-08-05Glucose [Mass/volume] in Serum or Plasma95mg/dL70-99 mg/dLNormalS
2026-08-05Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS
2026-08-05Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
2026-08-05Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-55 U/LNormalS
2026-08-05Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L8-48 U/LNormalS
2026-08-05Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma90U/L40-129 U/LNormalS
2026-08-05Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-08-05Thyrotropin [Units/volume] in Serum or Plasma6.8m[IU]/L0.4-4 mIU/LHighS
2026-08-05Thyroxine (T4) free [Mass/volume] in Serum or Plasma1ng/dL0.8-1.8 ng/dLNormalS
2026-08-05Cortisol [Mass/volume] in Serum or Plasma12.9ug/dLMorning (8 a.m.) reference intervalNormalS
2026-08-05Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Physical Exam

Vital signs recorded on 2026-08-05; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 75.2 kg; blood pressure 124/76, pulse 72; oxygen saturation 97 percent
NeckThyroid not enlarged or tender
RespiratoryClear throughout
CardiovascularRegular rhythm; no murmur
NeurologicalReflexes normal; no tremor

Problems

ProblemClinical statusVerificationCodeProvenance
Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review bookedresolvedconfirmed R91.1S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit.
Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alterationactiveconfirmed C34.12S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable.
Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicineactiveconfirmed F17.210S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission.
Acute viral upper respiratory infection (rhinovirus on a respiratory panel) on day 13 of cycle 2 of chemoimmunotherapy: runny nose, sore throat and a dry cough for three days, no hypoxia, clear chest X-ray; immune-related pneumonitis and pneumonia excluded; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingResponse imagingAfter the three cycles before surgeryCompleted todayCT five days ago: partial response, no new disease
LaboratoryBlood count with neutrophils and plateletsBefore surgeryCompleted todayHemoglobin 12.8 (low), white cells 6.2, neutrophils 3.6, platelets 188
LaboratoryChemistry before surgery: sodium, potassium, calcium, albumin, alkaline phosphataseBefore surgeryCompleted todaySodium 138, potassium 4.3, calcium 9.3, albumin 4.0, alkaline phosphatase 90
LaboratoryImmune-related adverse event laboratory panel: TSH, free T4, liver tests, creatinine and glucoseBefore each infusion and after the last doseCompleted todayTSH 6.8 (high) with free T4 1.0: subclinical thyroiditis, grade 1; ALT 31, AST 27, bilirubin 0.6; creatinine 1.1, eGFR 74; glucose 95
LaboratoryMorning cortisolBaseline and before each immunotherapy infusion (CMID); for symptomsCompleted today12.9 mcg/dL at 8 a.m., normal; drawn today as the corrective action for the gap recorded at cycle 2, which closes that deviation with no harm found
ImagingRepeat pulmonary function before surgeryIf symptoms or a clinical change after chemotherapyNot indicatedNo new breathlessness, and the values ten weeks ago were well above the thresholds; the surgeon agreed
Self-managementTobacco use and cessation treatmentEvery visitCompleted todayAbstinent nine weeks
SurveyDistress and depression screeningEvery visit; PHQ-9 and GAD-7 at diagnosis and at treatment transitionsCompleted todayPHQ-2 1
ExaminationDyspnea and cough assessmentEvery visitCompleted todayNo cough or breathlessness
ExaminationPeripheral neuropathy after platinumEvery visit during and after platinum therapyCompleted todayNone
Self-managementPulmonary rehabilitation (prehabilitation)Before lung resectionCompleted todayProgram of 16 sessions completed

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Brunelli A, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e166S-e190S (PMID 23649437) (2013); Howington JA, et al. Treatment of stage I and II non-small cell lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e278S-e313S (PMID 23649443) (2013); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021)

Follow-up: Lobectomy in two weeks. Visit six weeks after surgery with thyroid tests and the pathology. Call for fever, breathlessness or wound problems after the operation. Next scheduled visit 2026-09-30: six weeks after left upper lobectomy: pathology, surveillance plan, tobacco remission and pulmonary rehabilitation. [S]